Study on the mechanism of action of Guizhi Shaoyao Zhimu Decoction in the treatment of gout based on network pharmacology#br#
HE Jiaying1 LIU Mingling2 LI Shuyao1 WANG Xinyu1 GUAN Tong2
1.The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China;
2.Department of Rheumatology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China
Abstract：Objective To explore the mechanism of action of Guizhi Shaoyao Zhimu Decoction in the treatment of gout based on network pharmacology. Methods The active ingredients and corresponding targets of Guizhi Shaoyao Zhimu Decoction were screened by traditional Chinese medicine systems pharmacology database and analysis platform and literature. Gout related targets were searched by GeneCards, OMIM, DisGeNET and TTD databases, and the intersection of drugs and disease targets was obtained. Cytoscape 3.7.2 software was used to construct the disease-drug-target-component network and protein-protein interaction network, and R 4.0.3 software was used for GO enrichment analysis and KEGG pathway enrichment analysis. Results A total of 125 active components of Guizhi Shaoyao Zhimu Decoction and 60 drug-disease common targets were predicted. GO functional enrichment analysis mainly involved molecular functions such as phosphatase binding, metallopeptidase activity, MAPK activity, transcription factor binding, and oxidation-reduction enzyme activity. KEGG enrichment analysis showed that TNF signaling pathway, TLR signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, CLR signaling pathway, NF-κB signaling pathway were closely related to gout. Conclusion Guizhi Shaoyao Zhimu Decoction plays a significant role in the treatment of gout inflammation, uric acid metabolism disorder and bone destruction, and so on, providing theoretical basis for future clinical trials and experimental studies.
何家颖1 刘明岭2 李淑瑶1 王馨玉1 关彤2. 基于网络药理学探讨桂枝芍药知母汤治疗痛风的作用机制[J]. 中国医药导报, 2022, 19(1): 145-149.
HE Jiaying1 LIU Mingling2 LI Shuyao1 WANG Xinyu1 GUAN Tong2. Study on the mechanism of action of Guizhi Shaoyao Zhimu Decoction in the treatment of gout based on network pharmacology#br#. 中国医药导报, 2022, 19(1): 145-149.
[1] 曾小峰，陈耀龙.2016中国痛风诊疗指南[J].浙江医学，2017，39（21）：1823-1832.
[2] Engel B，Just J，Bleckwenn M，et al. Treatment Options for Gout [J]. Dtsch Arztebl Int，2017，114 （13）：215-222.
[3] 黄聪，彭伟，牟茂婷，等.基于“肢节痹病”的桂枝芍药知母汤的现代药理作用探讨[J].时珍国医国药，2019，30（4）：949-950.
[4] 邢心睿，吕狄亚，柴逸峰，等.网络药理学在中药作用机制中的研究进展[J].药学实践杂志，2018，36（2）：97-102.
[5] 潘显阳，陶金辉，李向培.痛风性关节炎发病的炎性机制研究进展[J].安徽医科大学学报，2021，56（7）：5.
[6] de Souza MR，de Paula CA，Pereira de Resende ML，et al. Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis：anti-hyperuricemic and anti-inflammatory effects of its extract，fraction and constituents [J]. J Ethnopharmacol，2012，142（3）：845-850.
[7] 杨杰，沙金丹，高翔，等.黄酮类化合物的免疫调节作用及机制[J].动物营养学报，2017，29（12）：4295-4300.
[8] Ruiz-Miyazawa KW，Staurengo-Ferrari L，Mizokami SS，et al. Quercetin inhibits gout arthritis in mice： induction of an opioid-dependent regulation of inflammasome [J]. Inflammopharmacology，2017. DOI：10.1007/s10787-017-0356-x.
[9] 姜华，胡立立，王紫玮，等.静脉给药防风色原酮单体药理活性对比研究[J].时珍国医国药，2016，27（7）：1575-1577.
[10] Han Xue，Liu Panpan，Liu Miaomiao，et al. Gingerol Ameliorates ISO-Induced Myocardial Fibrosis by Reducing Oxidative Stress，Inflammation，and Apoptosis through Inhibition of TLR4/MAPKs/NF-κB Pathway [J]. Mol Nutr Food Res，2020，64（13）. DOI：10.1002/mnfr.202000003.
[11] 郭璐，夏道宗，骆叶姣，等.基于网络药理学探讨土茯苓治疗痛风的作用机制[J].中草药，2019，50（6）：1413-1418.
[12] 朱春霞，顾祖莲，杨博，等.虎杖苷-桂皮醛对MSU诱导的THP-1细胞痛风性炎症模型的影响及机制[J].中药材，2017，40（7）：1710-1713.
[13] 刘威良，姬昱，黄艾祥.β-谷甾醇的研究及开发进展[J].农产品加工，2019（1）：77-79，82.
[14] Mohos V，Fliszár-Nyúl E，Poór M. Inhibition of Xanthine Oxidase-Catalyzed Xanthine and 6-Mercaptopurine Oxidation by Flavonoid Aglycones and Some of Their Conjugates [J]. Int J Mol Sci，2020，21（9）：3256.
[15] Ham SW，Jeon HY，Jin X，et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma [J]. Cell Death Differ，2019，26（3）：409-425.
[16] Yokose K，Sato S，Asano T，et al. TNF-α potentiates uric acid-induced interleukin-1β（IL-1β） secretion in human neutrophils [J]. Mod Rheumatol，2018，28（3）：513-517.
[17] Cavalcanti NG，Marques CD，Lins E Lins TU，et al. Cytokine Profile in Gout：Inflammation Driven by IL-6 and IL-18? [J]. Immunol Invest，2016，45（5）：383-395.
[18] Galván-Pe?觡a S，Carroll RG，Newman C，et al. Malonylation of GAPDH is an inflammatory signal in macrophages [J]. Nat Commun，2019，10（1）：338.
[19] 舒建龙，翟阳，徐文华，等.基于网络药理学-分子对接及实验研究探讨壮药痛风立安胶囊治疗痛风的作用机制[J].中药药理与临床：1-22. [2021-06-26]. https：//doi.org/10.13412/j.cnki.zyyl.20210615.004.
[20] Nissinen L，K?覿h?覿ri VM. Matrix metalloproteinases in inflammation [J]. Biochim Biophys Acta，2014，1840（8）：2571-2580.
[21] Schweyer S，Hemmerlein B，Radzun HJ，et al. Continuous recruitment，co-expression of tumour necrosis factor-alpha and matrix metalloproteinases，and apoptosis of macrophages in gout tophi [J]. Virchows Archiv，2000， 437（5）：534-539.
[22] 曾朝东，邹蓉，陈丽清，等.高尿酸血症对急性冠脉综合征患者动脉硬化影响分析[J].中国医药科学，2020，231（15）：252-254.
[23] 余乐，毛绍园，张秀灵，等.男性痛风患者血尿酸水平与血脂成分的相关性[J].广东医学，2019，40（3）：407-410，414.
[24] 李娜.维持性血液透析患者血尿酸水平与心血管疾病的关系研究[J].中国当代医药，2020，582（23）：17-20.
[25] Tatsiy O，Mayer TZ，de Carvalho Oliveira V，et al. Cytokine Production and NET Formation by Monosodium Urate-Activated Human Neutrophils Involves Early and Late Events，and Requires Upstream TAK1 and Syk [J]. Front Immunol，2020，10：2996.
[26] 廖攀，何懿，杨方圆，等.还原型谷胱甘肽对活性氧介导的系统性红斑狼疮患者中性粒细胞NETosis的影响[J].中国临床解剖学杂志，2018，36（5）：532-535.
[27] Yang S，Wang J，Brand DD，et al. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications [J]. Front Immunol，2018，9：784.
[28] Brown GD，Willment JA，Whitehead L. C-type lectins in immunity and homeostasis [J]. Nat Rev Immunol，2018， 18（6）：374-389.
[29] Raucci F，Iqbal AJ，Saviano A，et al. IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation [J]. Pharmacol Res，2019，147：104351.
京公网安备 11010502046598号